Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 6Phase 3 5Phase 4 2Phase NA 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Mammography 12Radiofrequency Ablation 9Blood Specimen Collection 9Standard of Care 8Drug Delivery Systems 8Colonoscopy 8Uterine Myomectomy 6Robotic Surgical Procedures 6Cryosurgery 6Colposcopy 6Biopsy 6Proton Therapy 5Inositol 5Therapeutics 4Surgical Procedures, Operative 4Radiotherapy 4Leukapheresis 4Food 4Drug Therapy 4Cryotherapy 4Cisplatin 4CF regimen 4Brachytherapy 4pegylated granulocyte colony-stimulating factor 3exemestane 3epigallocatechin gallate 3Uterine Artery Embolization 3Sunitinib 3Paclitaxel 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × INDUSTRY × bosutinib × Clear all
NCT01903733 2022-07-19

Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

Pfizer

Phase NA Completed
281 enrolled 24 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡